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Abstract
Background: The implementation of collaborative TB-HIV services is challenging. We, therefore, assessed TB
treatment outcomes in relation to HIV infection and antiretroviral therapy (ART) among TB patients attending a
primary care service with co-located ART and TB clinics in Cape Town, South Africa.
Methods: In this retrospective cohort study, all new TB patients aged ≥ 15 years who registered and initiated TB
treatment between 1 October 2009 and 30 June 2011 were identified from an electronic database. The effects of
HIV-infection and ART on TB treatment outcomes were analysed using a multinomial logistic regression model, in
which treatment success was the reference outcome.
Results: The 797 new TB patients included in the analysis were categorized as follows: HIV- negative, in 325
patients (40.8 %); HIV-positive on ART, in 339 patients (42.5 %) and HIV-positive not on ART, in 133 patients (16.7 %).
Overall, bivariate analyses showed no significant difference in death and default rates between HIV-positive TB
patients on ART and HIV-negative patients. Statistically significant higher mortality rates were found among HIV-
positive patients not on ART compared to HIV-negative patients (unadjusted odds ratio (OR) 3.25; 95 % confidence
interval (CI) 1.53–6.91). When multivariate analyses were conducted, the only significant difference between the
patient categories on TB treatment outcomes was that HIV-positive TB patients not on ART had significantly higher
mortality rates than HIV-negative patients (adjusted OR 4.12; 95 % CI 1.76–9.66). Among HIV-positive TB patients
(n = 472), 28.2 % deemed eligible did not initiate ART in spite of the co-location of TB and ART services. When
multivariate analyses were restricted to HIV-positive patients in the cohort, we found that being HIV-positive not on
ART was associated with higher mortality (adjusted OR 7.12; 95 % CI 2.95–18.47) and higher default rates (adjusted
OR 2.27; 95 % CI 1.15–4.47).
Conclusions: There was no significant difference in death and default rates between HIV-positive TB patients on
ART and HIV negative TB patients. Despite the co-location of services 28.2 % of 472 HIV-positive TB patients
deemed eligible did not initiate ART. These patients had a significantly higher death and default rates.
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Background
Tuberculosis (TB) is a global epidemic, with an esti-
mated 9.0 million new TB cases and 1.5 million deaths
in 2013[1]. The global burden of TB falls heaviest on 22
low- and middle-income countries, including those in
sub-Saharan Africa, where TB is fuelled by the HIV/
AIDS epidemic [1, 2]. In South Africa, there is a high
burden of both TB and HIV [1–3], and a high HIV-
associated TB case fatality rate [4].
In high TB and HIV prevalence settings such as
South Africa, patients accessing TB services can be
broadly categorized as HIV-negative TB patients or
HIV-positive TB patients. In terms of optimal case
management, both patient groups require standardized
anti-tuberculosis treatment, while HIV-positive TB pa-
tients also require trimethoprim-sulphamethoxazole
(co-trimoxazole) prophylaxis and antiretroviral treat-
ment (ART). ART results in a 64–95 % reduction in
mortality risk [5] and should be initiated early after
starting anti-tuberculosis treatment [6–8]. Compared to
their HIV-negative peers, HIV-positive TB patients are
a challenge to TB services, as they are more likely to
have diagnostic delays, are more likely to be infectious
for longer and, if not properly managed, may also have
poorer TB treatment outcomes [9]. Therefore, HIV in-
fection has the potential to profoundly impact on TB
treatment outcomes and is often the main reason for
failure to meet control targets in high HIV settings.
In order to control TB in high HIV prevalence set-
tings, the World Health organization (WHO) has rec-
ommended TB/HIV collaborative activities, whose
objectives are to create mechanisms for collaboration
between TB and HIV/AIDS programs, reduce the
burden of TB among people living with HIV and re-
duce the burden of HIV among TB patients [10]. The
interpretation of this recommendation varies as dem-
onstrated in a systematic review that described five
different models of TB/HIV service integration in
low-and middle- income countries, ranging from effi-
cient referral between services, to collaboration be-
tween HIV and TB services in the same health
facility, and to fully integrated services [11]. The ul-
timate goals of the models of integration are to re-
duce rates of mortality, default and relapse; improve
rates of TB cure and to prevent rates of drug resist-
ance. However, in practice challenges remain in the
implementation of TB/HIV collaborative activities. For
instance, ART uptake may be delayed due to patients
having high CD4 counts, drug stockout, patients’ fear
of drug interactions and overlapping side effects [12],
fear of clinicians and national health policy [13]. In
addition, the lack of integration of TB and HIV ser-
vices at all levels in the health system may negatively
impact the provision of care [14].
Numerous studies from sub-Saharan Africa have ex-
amined the impact of HIV infection on TB treatment
outcomes. These studies have yielded mixed results.
Some studies have demonstrated poorer TB treatment
outcomes in HIV-positive TB patients when compared
to HIV-negative TB patients [15–20], while others found
that TB treatment outcomes did not differ between the
two groups [21, 22]. In addition, the benefit of ART on
TB treatment outcomes has been demonstrated in re-
sults from the above-cited randomized controlled trials
[6–8] and observational studies [19, 23, 24]. Also, a re-
cent systematic review of studies conducted in sub-
Saharan Africa and elsewhere showed the benefit of
ART on TB mortality, and indicated a 44 to 71 % reduc-
tion in TB mortality risk [25].
TB mortality among HIV-positive TB patients is one
of the key indicators that measures the impact of collab-
orative TB/HIV activities [26]. With the advent of ART,
it has become increasingly clear that HIV-positive TB
patients are not a homogeneous group, and TB mortality
during TB treatment will differ between HIV-positive TB
patients on ART and those not on ART. However, to
date, there has been no study on TB mortality in HIV-
positive TB patients on ART relative to HIV-negative TB
patients. Also, to date, there has been no study on TB
mortality in HIV-positive TB patients not on ART
relative to HIV-negative TB patients.
The aim of the study, therefore, was to establish
whether there was a difference in the TB treatment out-
comes (mortality and treatment default) in HIV-positive
patients on ART compared to HIV-negative TB patients
and also among HIV-positive patients not on ART com-
pared to HIV-negative TB patients attending co-located
TB services in Cape Town, South Africa. In addition, we
aimed to examine impact of ART status and CD4 status




This was a retrospective cohort study conducted at the
Nyanga Community Health Centre. The Nyanga
Community Health Centre is situated in the Klipfontein
health sub-district, Cape Town, South Africa. An esti-
mated 420, 000 people [27] live in this predominantly
low-income urban community, which had an antenatal
HIV-1 prevalence rate of 24 % in 2009 [28]. This nurse-
run, doctor supported service provides TB and ART care
in two separate clinics run by different health authorities
but in the same building and has done so since the intro-
duction of an ART service in 2008. The Cape Town City
Health department was responsible for the TB services in
this clinic while the Western Cape Provincial Department
of Health introduced and managed the ART service.
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While ART and TB services were not fully integrated
in this clinic, the adherence support and the monitoring
and evaluation systems were partially integrated and all
patients starting ART or TB treatment were reviewed at
a weekly multidisciplinary team meeting which was
attended by TB and HIV staff. TB treatment was dis-
pensed by trained TB nurses under the supervision of a
clinician while ART was provided by a team comprised
of two clinical nurse practitioners and a doctor. This
study was conducted after the introduction of the ART
services to the clinic.
Inclusion and exclusion criteria
We included all new adult TB patients (aged ≥ 15 years)
who registered and initiated TB treatment between 1
October 2009 and 30 June 2011. We excluded those for
whom treatment outcomes were inconclusive (14 un-
known and 14 transferred out) or who failed treatment
(n = 20). We also excluded those for whom HIV status
was unknown (n = 13).
Data collection
Data from the Cape Town City Health electronic TB
register (ETR.net) were compared with that from the
Western Cape Department of Health’s electronic eKapa
TB and ART database and any differences were resolved
by reviewing patient folders and paper-based TB regis-
ters. The data are not freely available but permission for
access was obtained from Cape Town City Health and
Western Cape Department of Health. Variables for all
patients meeting the inclusion criteria were obtained
from the synchronized electronic TB register database.
Variables included TB registration number, registration
date, age, gender, HIV status, CD4 count at TB diagno-
sis, ART status and TB treatment outcome. Ethical ap-
proval for anonymized data collection was obtained
from the Research Ethics Committees of the University
of Cape Town and the International Union against
Tuberculosis and Lung Disease.
Outcome measures and definitions
For the purpose of this study, internationally recom-
mended definitions for TB treatment outcomes (classi-
fied as either cured, treatment completed, died,
defaulted or transferred out) [29] were used, in addition
to the category “unknown”. Cure was defined as the
presence of a negative sputum smear at the last month
of treatment and at least on one other occasion during
the course of treatment. Treatment completion referred
to a patient who completed treatment, but for whom
smear examination results were not complete enough to
classify the patient as cured; or based on clinical, radio-
logical and complementary examination criteria in those
patients who did not produce sputum for a smear
examination. Treatment success referred to the com-
bined number of patients belonging to the categories
“cured” and ‘treatment competed”. Death was defined as
all-cause mortality occurring after TB diagnosis and be-
fore the end of treatment. A patient was defined as a de-
faulter when he or she did not collect medicines for two
or more consecutive months.
Anti-tuberculosis and antiretroviral therapy
Standardized anti-tuberculosis regimens for new adult TB
cases consisted of a combination of rifampicin, isoniazid
pyrazinamide and ethambutol during the two initial
months (“intensive phase”) followed by rifampicin plus
isoniazid during four months (“continuation phase”) [30].
Antiretroviral therapy was offered according to the
South African ART guidelines that were updated once
during the study period. Before April 2010, staff at both
TB and ART services followed the 2004 South African
ART guidelines which recommended that patients with
CD4 counts of 50–200 cells/μL should delay ART until
after 2 months of starting TB treatment, while those
with a CD4 count <50 cells/μL or with serious co-
morbidities should commence ART as soon as possible
after at least 2 weeks of TB treatment [31]. After April
2010, the clinic staff were advised to adopt the 2010
South African ART guidelines, which recommended that
TB patients with CD4 cell counts <100 cells/μL or
WHO stage IV should commence ART within 2 weeks
of eligibility, and those with CD4 cell counts ≤350 cells/
μl should commence ART within 2–8 weeks of starting
TB treatment [32].
Statistical analysis
Patient characteristics were tabulated and stratified by
HIV and ART status (categorized as HIV-positive on
ART, HIV-positive not on ART and HIV-negative). The
chi-square test or Fisher’s exact test were used to com-
pare the distribution of categorical variables. The
Kruskal-Wallis test or Wilcoxon rank-sum was used to
compare the distribution of continuous variables.
The effects of HIV status, ART status and CD4 count
on TB treatment outcome were examined using multi-
nomial logistic regression models. In the multinomial lo-
gistic regression analysis, “treatment success” was the
reference category for the dependent variable, being
compared with the other categories (default versus treat-
ment success; death versus treatment success). Inde-
pendent variables were as follows: age (continuous);
gender (male or female); type of TB (smear-negative pul-
monary tuberculosis, smear-positive pulmonary tubercu-
losis or extra-pulmonary tuberculosis); CD4 count (<50,
50–199, 200–349 or ≥ 350 cells/ μL); HIV status (HIV-
positive on ART, HIV-positive not on ART or HIV-
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negative) and ART status (HIV-positive on ART or HIV-
positive not on ART).
All analyses were performed using STATA 12.1
(StataCorp, College Station, Texas, USA), and the level
of significance was set at P <0.05. 95 % confidence inter-
vals were also calculated throughout.
Results
A total of 918 new TB patients ≥ 15 years were regis-
tered between October 2009 and June 2011 (Fig. 1).
The new TB patients (n = 61) for whom HIV status
was unknown; tuberculosis treatment completion sta-
tus was inconclusive (unknown, transferred out) or
who failed tuberculosis treatment were exclude from
the analysis (Fig. 1). We also excluded 60 patient cat-
egorized as follows: not eligible for ART, in 29 and
unknown ART eligibility in 31 patients. This left 797
patients who formed the patient cohort in the study.
HIV status in this sample was categorized as follows:
HIV- negative, in 325 patients (40.8 %); HIV-positive
on ART, in 339 patients (42.5 %) and HIV-positive
not on ART, in 133 patients (16.7 %).
The proportion of patients who were female was
higher among patients categorized as HIV-positive on
ART and HIV positive not on ART (60.8 % and 60.2 %,
respectively) (Table 1). The proportion of patients who
had smear-positive TB was higher among those HIV-
negative (P < 0.001). In contrast, no significant differ-
ences were found in the distribution of age for each
category. The death rate was higher among HIV-positive
not on ART compared to the other categories (P < 0.001)
(Table 1).
Among HIV-positive TB patients (n = 472), the me-
dian CD4 count was higher in patients categorized
HIV-positive not on ART than HIV-positive on ART
(P < 0.0001) (Table 1). Just over one quarter (28.2 %)
of HIV-positive TB patients deemed eligible did not
initiate ART during their TB treatment (Fig. 1).
The findings of multinomial logistic regression ana-
lysis of the factors associated with treatment out-
comes in new TB patients can be found in Table 2.
The odds ratio (OR) for death in relation to treat-
ment success was found to be significantly higher in
patients HIV positive not on ART (adjusted OR 4.12;
95 % confidence interval (CI) 1.76–9.66) than in those
HIV-negative. Increased age was associated with
higher death rates in relation to treatment success
(adjusted OR 1.04; 95 % CI 1.02–1.07) but reduced
default rates in relation to treatment success (adjusted
OR 0.98; 95 % CI 0.96–1.00). In addition, being fe-
male was associated with lower default rates in rela-
tion to treatment success (adjusted OR 0.57; 95 % CI
0.35–0.91).
Table 3 shows the findings of the multinomial regression
analysis of the factors associated with treatment outcomes
in HIV–positive TB patients. The odds ratio for death in
relation to treatment success was found to be higher in
patients HIV-positive not on ART (adjusted OR 7.38;
95 % CI 2.95–18.47) than in those HIV-positive on ART.
Similarly, the odds ratio for default in relation to treat-
ment success was found to be higher in patients HIV posi-
tive not on ART (adjusted OR 2.27; 95 % CI 1.15–4.47)
than in those HIV positive on ART. In addition, increase
age was associated with higher death rates in relation to
treatment success (adjusted OR 1.05; 95 % CI 1.01–1.10).
Fig. 1 Flow diagram showing the HIV status and uptake of antiretroviral treatment for new TB patients≥ 15 years who were registered between
October 2009 and June 2011
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HIV positive on ART
N (%)






Median, IQR 33 (26–42) 33 (28–39) 33 (27–37) 32 (23–48) Kruskal-Wallis 0.332
Gender
Female 408 (51.2) 206 (60.8) 80 (60.2) 122 (37.5) Chi-square <0.001
Male 389 (48.8) 133 (39.2) 53 (39.9) 203 (62.5)
Type of TB
Smear-negative PTB 242 (30.4) 109 (32.2) 52 (39.1) 81 (24.9) Chi-square <0.001
Smear-positive PTB 357 (44.8) 104 (30.7) 48 (36.1) 205 (63.1)
EPTB 198 (24.8) 126 (37.2) 33 (24.8) 39 (12.0)
CD4 count, cells/μL
Median, IQR 144 (74–249) 123 (66–203) 223.5 (109–386) - Wilcoxon rank-sum <0.0001
<200 302 (65.0) 247 (73.7) 55 (42.3) - Chi-square <0.001
200–349 115 (24.7) 77 (23.0) 38 (29.2) -
350-499 30 (6.5) 7 (2.1) 23 (17.7) -
≥500 18 (3.9) 4 (1.2) 14 (10.8) -
TB treatment outcome
Successa 668 (83.8) 299 (88.2) 96 (72.2) 273 (84.0) Chi-square <0.001
Defaulted 88 (11.0) 29 (8.6) 21 (15.8) 38 (11.7)
Died 41 (5.1) 11 (3.2) 16 | (12.0) 14 (4.3)
Total 797 (100.0) 339 (42.5) 133 (16.7) 325 (40.8) -
IQR interquartile range
Percentages may not add up to 100 due to rounding
aDefined as cured and treatment completed
Table 2 Multinomial logistic regression of factors associated with treatment outcomes in new TB patients
Defaulted vs. Successa Died vs. Successa Defaulted vs. Successa Died vs. Successa
Unadjusted OR (95 % CI) Unadjusted OR (95 % CI) Adjusted OR (95 % CI)b Adjusted OR (95 % CI)b
Age, years 0.98 (0.96–1.00) 1.03** (1.01–1.05) 0.98* (0.96–1.00) 1.04** (1.02–1.07)
Gender
Male Ref. Ref. Ref. Ref.
Female 0.60* (0.38–0.94) 1.16 (0.62–2.19) 0.57* (0.35–0.91) 1.06 (0.55–2.06)
Type of TB
EPTB Ref. Ref. Ref. Ref.
Smear-negative PTB 0.98 (0.54–1.77) 0.81 (0.36–1.79) 0.88 (0.48–1.62) 0.60 (0.26–1.39)
Smear-positive PTB 0.85 (0.49–1.49) 0.61 (0.29–1.32) 0.69 (0.38–1.26) 0.59 (0.26–1.34)
HIV status
HIV-negative Ref. Ref. Ref. Ref.
HIV-positive on ART 0.70 (0.41–1.16) 0.72 (0.32–1.61) 0.71 (0.41–1.23) 0.80 (0.33–1.95)
HIV- positive not on ART 1.57 (0.88–2.81) 3.25** (1.53–6.91) 1.62 (0.88–2.97) 4.12** (1.76–9.66)
Ref. reference, EPTB extra-pulmonary tuberculosis, OR odds ratio, 95 % CI, 95 % confidence intervals
* p < .05, ** p < .01, *** p < .001
aSuccess defined as cured and treatment completed
bAdjusted for age, gender, type of TB and HIV
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In patients with a CD4 count 200–349 cells/μL,
compared to those with CD4 cell counts <50 cells/μL,
the odds ratio for death in relation to treatment suc-
cess was low (adjusted OR 0.20; 95 % CI 0.05 –
0.75). Similarly, the odds ratio for death in relation to
treatment success was found to be lower in patients
with CD4 count cell counts ≥350 cells cells/μL
(adjusted OR 0.14; 95 % CI 0.03–0.77) compared to
those with CD4 cell counts <50 cells/μL.
Discussion
In this study, that assessed the impact of HIV, ART sta-
tus and CD4 cell count on TB treatment outcomes
among 797 new TB patients in a co-located ART and TB
clinic, death and default rates were significantly higher
among HIV-positive patients not on ART than HIV-
negative patients. However, there were no differences in
death and default rates between HIV-positive TB pa-
tients on ART and the HIV negative TB patients. ART
uptake during the TB treatment episode was shown to
significantly improve mortality and default rates for the
HIV-positive TB patients.
Relatively poor uptake of ART has been reported in
other studies on various forms of integrated ART and
TB services and our finding that 28.2 % of 472 HIV-
positive TB patients deemed eligible did not initiate ART
during TB treatment in spite of co-location of TB and
ART services lies within the range of 27.3 % and 62 %
reported in sub-Saharan Africa programs providing fully
integrated TB and ART services [12, 13, 19, 33] and is
lower than the range of 66–86 % reported in geographic-
ally separate services [34–36]. Therefore, the barriers to
successful uptake of ART seem common to all studies
regardless of the model of care applied. These data
clearly indicate that ART uptake should be improved
within this setting of co-located TB and ART services or
that there is a requirement for a different model of inte-
gration of services that would provide for a closer moni-
toring of ART uptake in patients with HIV-associated
TB. Owing to the retrospective design of this study, the
barriers to ART uptake were unknown.
Our study finding that ART uptake during TB treat-
ment was significantly associated with improved mortal-
ity rates, is similar to a study among patients accessing
an integrated TB and ART service in Malawi [19] and is
in keeping with evidence that ART during TB treatment
improves survival from a randomized controlled trial
conducted in South Africa [37]. The study findings call
for the strengthening of HIV/TB collaborative activities
to ensure efficient treatment integration, which could
lead to improved TB treatment outcomes HIV-positive
TB patients. However, this community health centre has
two health authorities rendering either TB or ART ser-
vices that are not harmonized owing to organizational
differences. Therefore, there is a need to unify these sep-
arate health authorities at all levels of the health system
Table 3 Multinomial logistic regression of factors associated with treatment outcomes in HIV-positive TB patients
Defaulted vs. Successa Died vs. Successa Defaulted vs. Successa Died vs. Successa
Unadjusted OR (95 % CI) Unadjusted OR (95 % CI) Adjusted OR (95 % CI) Adjusted OR (95 % CI)
Age, years 1.00 (0.97–1.03) 1.04* (1.01–1.09) 1.00 (0.96–1.03) 1.05* (1.01–1.10)
Gender
Male Ref. Ref. Ref. Ref.
Female 0.74 (0.41–1.34) 1.08 (0.48–2.41) 0.75 (0.40–1.40) 1.65 (0.66–4.11)
Type of TB
EPTB Ref. Ref. Ref. Ref.
Smear-negative PTB 1.21 (0.59–2.45) 1.13 (0.44–2.87) 1.05 (0.51–2.18) 0.74 (0.26–2.07)
Smear-positive PTB 0.97 (0.46–2.05) 0.92 (0.34–2.47) 0.85 (0.40–1.82) 0.68 (0.23–2.01)
CD4 count, cells/μL
<50 Ref. Ref. Ref. Ref.
50–199 0.73 (0.32–1.67) 0.43 (0.16–1.11) 0.79 (0.34–1.85) 0.42 (0.15–1.17)
200–349 0.88 (0.36–2.19) 0.31 (0.09–1.06) 0.84 (0.33–2.15) 0.20* (0.05–0.75)
≥350 1.20 (0.41–3.48) 0.39 (0.08–1.91) 0.84 (0.26–2.68) 0.14* (0.03–0.77)
ART status
HIV-positive on ART Ref. Ref. Ref. Ref.
HIV- positive not on ART 2.26** (1.23–4.14) 4.53*** (2.03–10.10) 2.27* (1.15–4.47) 7.38*** (2.95–18.47)
Ref. reference, EPTB extra-pulmonary tuberculosis, OR odds ratio, 95 % CI 95 % confidence intervals
* p < .05, ** p < .01, *** p < .001
aSuccess defined as cured and treatment completed
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(which range from clinical care to community support
and administrative structures) in order for the commu-
nity health centre to ensure the successful delivery of in-
tegrated TB and ART care for HIV-positive TB patients.
Similar to other studies from sub-Saharan Africa and
elsewhere [5–8, 37–45], we found that higher CD4 cell
counts (≥200 cells/μL) were associated with reduced
mortality, an indication that patients with CD4 counts
<200 cells/μL) should be fast-tracked for ART. This,
however, may only be achieved if ART is prescribed and
administered by the TB services.
The strength of this study is that it provides an insight
into the HIV, ART status and CD4 cell count on TB treat-
ment outcomes among new TB patients attending a TB
service co-located within the same facility as an ART ser-
vice, although the two services remain separately staffed.
The study findings, therefore, are useful to inform policy
and programs that aim to improve TB treatment out-
comes among new patients with HIV-associated TB in
this TB service and other comparable settings.
The limitations of the data used in present study
must be acknowledged. We used only routinely col-
lected program data which did not have details of
HIV-RNA viral loads of patients and antiretroviral
treatment histories of patients already on ART at the
time of TB diagnosis (such as antiretroviral resistance,
virological treatment failure and clinical immuno-
logical failure). The study, therefore, could not ex-
plore the effect of these factors on TB treatment
outcomes. In addition, non-randomized studies are
subject to possible residual confounding bias by un-
measured confounders. Due to small numbers, we
could not explore the effect of duration on ART or
time delay of ART initiation on treatment outcomes.
A further limitation of our study was that the rou-
tinely collected program data available did not have
details regarding TB culture results or the distribution
of drug resistant versus drug sensitive forms of TB in
the study population. Therefore, the study could not
determine the influence of these factors on TB treat-
ment outcomes.
Conclusions
In conclusion, this study showed that death rates were
similar for HIV-positive TB patients on ART and HIV-
negative TB patients but were considerably higher among
HIV-positive patients not on ART. Moreover, despite the
co-location of TB and ART services in the same building
28.2 % of 472 HIV-positive TB patients who were eligible
to start ART did not initiate ART during the TB treatment
episode. These patients had significantly higher death
rates and default rates. These findings stress the need for
an intervention aimed at improving ART uptake targeting
both patients and health care providers.
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